文献速递关节外科

全关节置换术中新兴非阿片类镇痛策略:机制、证据与实践实施

Emerging Nonopioid Analgesic Strategies in Total Joint Arthroplasty: Mechanisms, Evidence, and Practical Implementation.
PubMed 文献 · J Arthroplasty · 2026-03-30

本文综述了全关节置换术(TJA)后非阿片类镇痛策略的机制、证据与实施。新型药物如suzetrigine、静脉美洛昔康和缓释脂质体布比卡因显示阿片节俭效应;非药物 adjuncts 如TENS、超声和针灸提供互补获益。多模式阿片节俭方案最平衡,但受成本、可及性和缺乏关节置换特异性试验限制。

要点

  • 新型非阿片药物(suzetrigine、静脉美洛昔康、缓释脂质体布比卡因)具有阿片节俭效应和良好耐受性。
  • 非药物疗法(TENS、持续声医学超声、针灸)通过调节外周和中枢敏化提供互补获益。
  • 可注射水凝胶和聚合物递送系统可延长局部镇痛超过72小时。

核心结论

  • 结合药物和非药物药物的多模式阿片节俭方案为TJA后疼痛管理提供最平衡的方法。
  • 更广泛实施受成本、可及性和缺乏关节置换特异性试验限制。

研究设计与样本

  • 综述总结了与TJA临床相关的当前和新兴非阿片类镇痛模式,分析了近期随机对照试验、荟萃分析和监管更新。

主要发现

  • suzetrigine(VX-548)是一种选择性电压门控钠1.8通道阻滞剂,具有阿片节俭效应。
  • 静脉美洛昔康是一种肠外COX-2抑制剂,具有阿片节俭效应。
  • 缓释脂质体布比卡因具有阿片节俭效应和良好耐受性。
  • 经皮电神经刺激、持续声医学超声和针灸通过调节外周和中枢敏化提供互补获益。
  • 可注射水凝胶和聚合物基递送系统有潜力将疼痛控制延长至72小时以上。

关键数值与推荐

  • 2025年实施的《Non-Opioids Prevent Addiction in the Nation Act》扩大了 Medicare 对非阿片类疼痛治疗的报销。

临床怎么用

  • 纳入药物和非药物药物的多模式阿片节俭方案可用于TJA后疼痛管理。
  • 考虑使用新型非阿片药物和非药物 adjuncts 以减少阿片类药物使用。

局限性

  • 更广泛实施受成本、可及性和缺乏关节置换特异性试验限制。
  • 需要更广泛的临床验证和经济分析以建立可持续、以患者为中心的术后疼痛控制模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total joint arthroplasty (TJA), encompassing total hip and knee arthroplasty, remains one of the most effective procedures for end-stage arthritis, but is frequently associated with substantial postoperative pain. Opioid-based analgesia, although effective, carries risks of dependence, respiratory depression, and delayed recovery. In response to the opioid crisis, multimodal nonopioid strategies have gained prominence to improve outcomes while minimizing adverse effects. METHODS: This review summarized current and emerging nonopioid analgesic modalities with clinical relevance to TJA. Recent randomized controlled trials, meta-analyses, and regulatory updates were analyzed to evaluate efficacy, safety, and practical integration into perioperative care. RESULTS: Novel pharmacologic options-including suzetrigine (VX-548), a selective voltage-gated sodium 1.8 sodium channel blocker; intravenous meloxicam, a parenteral COX-2 inhibitor; and extended-release liposomal bupivacaine, demonstrate meaningful opioid-sparing effects with favorable tolerability profiles. Adjunctive nonpharmacologic modalities such as transcutaneous electrical nerve stimulation, sustained-acoustic-medicine ultrasound, and acupuncture offer complementary benefits by modulating peripheral and central sensitization. In addition, injectable hydrogel and polymer-based delivery systems represent a next generation of sustained local analgesia with the potential to extend pain control beyond 72 hours. The Non-Opioids Prevent Addiction in the Nation Act, implemented in 2025, expands Medicare reimbursement for nonopioid pain treatments, providing a key policy incentive for adoption in surgical care. CONCLUSIONS: Multimodal, opioid-sparing regimens that incorporate both pharmacologic and nonpharmacologic agents offer the most balanced approach to pain management after TJA. Although promising, wider implementation is limited by cost, access, and a paucity of arthroplasty-specific trials. Future directions include integration of artificial intelligence to individualize regimens, use of predictive pain algorithms, and real-time physiologic pain monitoring. Broader clinical validation and economic analyses are essential to establish sustainable, patient-centered models of postoperative pain control.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Siddiqi A, Chen AF, Jacob P, et al. Emerging Nonopioid Analgesic Strategies in Total Joint Arthroplasty: Mechanisms, Evidence, and Practical Implementation. J Arthroplasty. 2026. PMID: 41921832. doi:10.1016/j.arth.2026.03.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。